En la prctica, esto se traduce en tres grandes beneficios clnicos con evidencia slida de ensayos fase III: una reduccin de peso de hasta el 22,5% en personas con obesidad sin diabetes, una normalizacin de la glucemia en el 94,5% de los prediabticos a tres aos, y una reduccin del 38% en los eventos de insuficiencia cardiaca en pacientes con ICFEp y obesidad
It touches general practice, endocrinology, obesity medicine, cardiology, pharmacy, dietetics, consumer health behaviour, and government reimbursement
For those in the U.S., this is readily accessible, with physician oversight, and U.S.-compounded product
Do it now
( This is why it is so important to be a part of a team that is monitoring and regulating your progress.) However for patients with a long history of being overweight or obese the indication is for long-term maintenance dosing
Brightmeds promotional first-month pricing may be time-limited